HAEMOPHILUS INFLUENZAE TYPE B STRAIN 20752 CAPSULAR POLYSACCHARIDE TETANUS TOXOID CONJUGATE ANTIGEN
drugOn this page
Also known as Hiberix
Summary
Haemophilus Influenzae Type B Strain 20752 Capsular Polysaccharide Tetanus Toxoid Conjugate Antigen (CHEMBL4297977) is a phase-3 clinical-stage vaccine component; indicated across 3 conditions including meningococcal infection and streptococcal infection.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Vaccine component
- Indications: 3 conditions
- Clinical trials: 9
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4297977 |
| Name | HAEMOPHILUS INFLUENZAE TYPE B STRAIN 20752 CAPSULAR POLYSACCHARIDE TETANUS TOXOID CONJUGATE ANTIGEN |
| Type | Vaccine component |
| Max phase | 3 |
Also known as: Hiberix
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| meningococcal infection | 3 | MONDO:0005373 | EFO:0004249 |
| streptococcal infection | 3 | MONDO:0021680 | EFO:1001476 |
| Rotavirus infection | 3 | MONDO:0005194 | EFO:0002622 |
Clinical trials
Total trials: 9.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 9 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00136604 | PHASE3 | COMPLETED | Response to GSK Biologicals’ Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m |
| NCT00228917 | PHASE3 | COMPLETED | Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children |
| NCT00344318 | PHASE3 | COMPLETED | Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals’ 10-valent Pneumococcal Conjugate Vaccine |
| NCT00412854 | PHASE3 | COMPLETED | Study to Assess Safety & Immunogenicity of GSK Biologicals’ DTPa/Hib Vaccine vs Separate Administration of DTPa and Hib. |
| NCT00547248 | PHASE3 | COMPLETED | Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines |
| NCT00814710 | PHASE3 | COMPLETED | Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age |
| NCT02096263 | PHASE3 | COMPLETED | Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants |
| NCT03207750 | PHASE3 | COMPLETED | This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals’ Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK’s Licensed Lyophilized Vaccine |
| NCT03621670 | PHASE3 | COMPLETED | Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).